[go: up one dir, main page]

CN106660995A - 一种达比加群环基酯衍生物及其制备方法和在药学上的用途 - Google Patents

一种达比加群环基酯衍生物及其制备方法和在药学上的用途 Download PDF

Info

Publication number
CN106660995A
CN106660995A CN201580036812.4A CN201580036812A CN106660995A CN 106660995 A CN106660995 A CN 106660995A CN 201580036812 A CN201580036812 A CN 201580036812A CN 106660995 A CN106660995 A CN 106660995A
Authority
CN
China
Prior art keywords
methyl
amino
carbonyl
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580036812.4A
Other languages
English (en)
Inventor
魏用刚
邱关鹏
雷柏林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Haisco Pharmaceutical Co Ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Publication of CN106660995A publication Critical patent/CN106660995A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明涉及一种通式(I)所示的达比加群环基酯衍生物及其立体异构体或药学上可接受的盐，以及在制备用于预防和治疗血栓栓塞疾病的药物中的用途，结构如式(I)所示，X1、X2、R1、R2的定义与说明书一致。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201580036812.4A 2014-08-06 2015-08-04 一种达比加群环基酯衍生物及其制备方法和在药学上的用途 Pending CN106660995A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410383909 2014-08-06
CN201410383909X 2014-08-06
CN2015102011768 2015-04-27
CN201510201176 2015-04-27
PCT/CN2015/086016 WO2016019844A1 (zh) 2014-08-06 2015-08-04 一种达比加群环基酯衍生物及其制备方法和在药学上的用途

Publications (1)

Publication Number Publication Date
CN106660995A true CN106660995A (zh) 2017-05-10

Family

ID=55263147

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580036812.4A Pending CN106660995A (zh) 2014-08-06 2015-08-04 一种达比加群环基酯衍生物及其制备方法和在药学上的用途

Country Status (2)

Country Link
CN (1) CN106660995A (zh)
WO (1) WO2016019844A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102838588A (zh) * 2011-06-24 2012-12-26 中国药科大学 一类可用于口服的凝血酶抑制剂、其制法以及医药用途
CN102875533A (zh) * 2012-11-06 2013-01-16 中国药科大学 达比加群衍生物、其制法及抗血栓用途
CN103044404A (zh) * 2013-01-14 2013-04-17 中国药科大学 达比加群衍生物、其制法及抗血栓用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102838588A (zh) * 2011-06-24 2012-12-26 中国药科大学 一类可用于口服的凝血酶抑制剂、其制法以及医药用途
CN102875533A (zh) * 2012-11-06 2013-01-16 中国药科大学 达比加群衍生物、其制法及抗血栓用途
CN103044404A (zh) * 2013-01-14 2013-04-17 中国药科大学 达比加群衍生物、其制法及抗血栓用途

Also Published As

Publication number Publication date
WO2016019844A1 (zh) 2016-02-11

Similar Documents

Publication Publication Date Title
JP7046968B2 (ja) ２－（置換フェニルヘテロ）芳香族カルボン酸系ｆｔｏ阻害剤、その製造方法およびその使用
CN101362718B (zh) 4-(4-苯甲酰氨基苯氧基)-2-(甲基氨甲酰基)吡啶衍生物及其制备方法和用途
JP2018021048A (ja) 強力な尿酸トランスポーター阻害剤の開発：それらの尿酸排泄効果のために設計された化合物
TW200911245A (en) Pyridone derivatives
TWI837402B (zh) 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途
KR102637487B1 (ko) Dpp-4 억제제인 벤조 6원 고리 유도체 및 이의 응용
CA2646430A1 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
KR101391746B1 (ko) 인다논 유도체, 이의 약학적으로 허용되는 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
JP2003520270A (ja) ミクロソームトリグリセリド輸送タンパク質およびアポリポタンパク質分泌の阻害剤として有用なカルボキサミド
CN114710956A (zh) 抑制perk的吡咯并嘧啶化合物
KR20220068224A (ko) Perk 억제 화합물
CN110305045A (zh) 一种酰胺类化合物及其在治疗癌症中的用途
KR102882178B1 (ko) 신규한 디펩티드 화합물과 이의 용도
TWI817191B (zh) 新穎聯芳基衍生物及其作為針對二醯基甘油醯基轉移酶２之抑制劑之用途
EA003327B1 (ru) Антивирусные соединения
CN106660995A (zh) 一种达比加群环基酯衍生物及其制备方法和在药学上的用途
WO2003086396A9 (en) Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative
CN109096177A (zh) 3－酰胺基苯甲酸衍生物、其制备方法及医药用途
CN106536504A (zh) 一种氟代达比加群酯衍生物及其制备方法和在药学上的用途
TWI682928B (zh) 達比加群烷酯衍生物及其製備方法和在藥學上的用途
CN106536505A (zh) 一种达比加群烷酯衍生物及其制备方法和在药学上的用途
CN107162913B (zh) 一类新型氘代苯丙酸衍生物、其制备方法及其作为药物的用途
JPH0662621B2 (ja) 新規芳香族化合物、その製造法及び該化合物を含有する心臓脈管薬
CN106470987A (zh) 一种达比加群酯衍生物及其制备方法和在药学上的用途
CN102382037B (zh) 苯丙酸类化合物及其制法和药物用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170510

WD01 Invention patent application deemed withdrawn after publication